GlassScriptPhysician profile
Kaavya Chivukula
NPI 1376070961
$4,646.62
in general payments reported to CMS, 2019-2025
43 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.31 · 2021: $632 · 2022: $651 · 2023: $1,184 · 2024: $1,150 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.78 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $761.19 | 2023-2025 | Veozah |
| Novo Nordisk INC | $584.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $442.66 | 2020-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $415.84 | 2021-2025 | Ubrelvy, Vraylar, Botox |
| Glaxosmithkline, LLC. | $303.29 | 2022-2025 | Arexvy, Shingrix, Penmenvy |
| Lilly USA, LLC | $288.80 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $253.72 | 2021-2024 | Airsupra, Farxiga |
| Pfizer INC. | $174.95 | 2022-2025 | |
| Tris Pharma INC | $109.53 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $88.08 | 2021-2024 | Trintellix |
| Corium, LLC | $81.25 | 2023-2025 | Azstarys |
| Esperion Therapeutics, INC. | $74.39 | 2021-2023 | Nexletol |
| Daiichi Sankyo INC. | $74.18 | 2021-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.69 | 2023-2025 | Xifaxan, Cycloset |
| Biohaven Pharmaceutical Holding Company LTD. | $68.88 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaavya Chivukula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.